Published by Iain Gilbert on 7th November 2017
(ShareCast News) - British biotechnology firm Oxford BioDynamics has entered into an initial collaboration with an unnamed US biopharmaceutical company in order to advance both the discovery and development of treatments for abnormal wound healing responses that lead to fibrosis, a pathological feature of most chronic inflammatory diseases.